Breaking News
January 20, 2018 - MSU scientists seek to identify brain mechanisms related to psychosis
January 20, 2018 - Syndax Pharmaceuticals Announces Clinical Collaboration to Evaluate Entinostat in Combination with anti-PD-L1 Cancer Immunotherapy in Breast Cancer
January 20, 2018 - Endoscopes Over Microscopes in Retinal Surgery: Ophthalmology Times
January 20, 2018 - Technology not taking over children’s lives despite screen-time increase
January 20, 2018 - Study finds extensive contamination around lead battery recycling plants in 7 African countries
January 20, 2018 - Flu may pass to others through exhaled breath, study shows
January 20, 2018 - Neuronal loss very limited in Alzheimer’s disease, new study shows
January 20, 2018 - Novel robot can aid treatment of rare birth defect
January 19, 2018 - TherapeuticsMD Announces Submission of New Drug Application for TX-001HR
January 19, 2018 - Fighting Infant Mortality | Medpage Today
January 19, 2018 - Researchers offer new evidence on four-year-old children’s knowledge about ecology
January 19, 2018 - Analysis finds overlooked crucial factor in determining prognosis for DIPGs
January 19, 2018 - Review explores consequences of genetic testing and cancer risk-reducing surgery
January 19, 2018 - Morning Break: HHS Div. of Religious Freedom; Trump’s Heart Health; Minister of Loneliness
January 19, 2018 - Parkinson’s disease ‘jerking’ side effect detected by algorithm
January 19, 2018 - New analysis finds dramatic increases in maternal mortality rates
January 19, 2018 - Weight-Loss Surgery’s Benefits Wane Over Time for Diabetics
January 19, 2018 - Cath Lab Recap: Sapien 3 Delivery System Recall; Transatlantic PCI Smackdown
January 19, 2018 - Parkinson’s treatment could be more effective, student finds
January 19, 2018 - New vaccine approach offers effective protection against tuberculosis
January 19, 2018 - Home care agencies often wrongly deny Medicare help to the chronically ill
January 19, 2018 - One hundred percent fruit juice does not alter blood sugar levels
January 19, 2018 - Prebiotics could enhance learning and memory skills in infants
January 19, 2018 - CMS May Cover MRI With Cardiac Devices Across the Board
January 19, 2018 - As income rises, women get slimmer—but not men
January 19, 2018 - Researchers develop adhesive materials to prevent bracket stains on teeth
January 19, 2018 - Flu can be spread without coughs and sneezes
January 19, 2018 - AMSBIO’s new recombinant protein shows great promise for organoid culture
January 19, 2018 - AbbVie’s Upadacitinib Granted Breakthrough Therapy Designation from the U.S. Food and Drug Administration for Atopic Dermatitis
January 19, 2018 - ASH: Pomalidomide Dose Escalation Improves Response
January 19, 2018 - Is your child’s school an obesity risk?
January 19, 2018 - Scientists describe groundbreaking training effect on the innate immune system
January 19, 2018 - MAST announces new AmpC, ESBL & Carbapenemase Detection Set
January 19, 2018 - Signaling molecules likely involved in concussions, rodent studies show
January 19, 2018 - Mast introduces Carba plus for CPE and OXA-48 confirmation
January 19, 2018 - Paleolithic diet helps overweight women maintain weight loss
January 19, 2018 - Agios Submits New Drug Application to the FDA for Ivosidenib for the Treatment of Patients with Relapsed/Refractory AML and an IDH1 Mutation
January 19, 2018 - This Flu Season, Don’t Forget About Tamiflu
January 19, 2018 - Amsterdam wins battle to host EU medicines agency after Brexit
January 19, 2018 - Study suggests movement as accurate method to diagnose neurodevelopmental disorders
January 19, 2018 - Maximize resolution in deep imaging for neuroscience research with Olympus TruResolution objectives
January 19, 2018 - Bilingualism may benefit children with ASD
January 19, 2018 - FDA Alert: Levofloxacin in 5 Percent Dextrose 250mg/50mL by AuroMedics: Recall
January 19, 2018 - USPSTF Not Backing Ankle-Brachial Index, CRP, or Coronary Calcium
January 19, 2018 - Higher omega-3 fatty acid intake tied to lower glaucoma risk
January 19, 2018 - Findings reveal conventional cancer therapy as double-edged sword
January 19, 2018 - Health Highlights: Jan. 16, 2018
January 19, 2018 - Morning Break: Anti-Emetic Warning; Uninsured Rate Jumps; Flu Worsens Saline Shortage
January 19, 2018 - Increased use of ambulatory surgery centers for cataract surgery
January 19, 2018 - Not-for-profit hospitals coming up with their own generic medicines to combat shortages
January 19, 2018 - $500 cancer detection blood tests may soon become reality
January 19, 2018 - Chronic traumatic encephalopathy may start early even without signs of concussions
January 19, 2018 - Warm-up program for children cuts soccer injuries by 50%
January 19, 2018 - ‘You’re Old and You Need Tests’: What We Heard This Week
January 19, 2018 - Egg-preserving hysterectomy raises heart risks later: study
January 19, 2018 - GA-map Dysbiosis Test identifies IBS patients who respond to FODMAP diet, study shows
January 19, 2018 - Study explores mortality and health-related habits in former elite athletes and their brothers
January 19, 2018 - New biodegradable sensors could assist doctors
January 19, 2018 - Modular gene enhancers may be suitable target in treatment of blood cancer
January 18, 2018 - New precision medicine trial for metastatic pancreatic cancer
January 18, 2018 - Shire Receives FDA Breakthrough Therapy Designation for Maribavir, an Investigational Treatment for Cytomegalovirus (CMV) Infection in Transplant Patients
January 18, 2018 - Pre-Existing Patient-Valve Mismatch Trips Up ViV Implant
January 18, 2018 - Adolescents: health risks and solutions
January 18, 2018 - US woman delivers baby from embryo frozen for 24 years
January 18, 2018 - Study identifies new target for treatment of depression
January 18, 2018 - LJI study reveals key player that promotes skin inflammation in atopic dermatitis
January 18, 2018 - Study devises efficient and economical strategy to screen breast and ovarian cancer gene mutations
January 18, 2018 - Agile Therapeutics, Inc. Receives a Complete Response Letter from the FDA for Twirla (AG200-15) for the Prevention of Pregnancy
January 18, 2018 - Gene Therapy for Inherited Retinal Dystrophy Gets FDA Clearance
January 18, 2018 - Researchers identify a new chemical pathway that helps the brain detect sweet, savory and bitter flavors
January 18, 2018 - IBV develops platform that helps companies to diagnose wellbeing of their workforce
January 18, 2018 - Study to test new precision medicine approach for metastatic pancreatic cancer
January 18, 2018 - World’s first vaccine relieves grass pollen allergy symptoms by at least 25%, study shows
January 18, 2018 - FDA Approves New Indication for Gilotrif (afatinib) in EGFR Mutation-Positive NSCLC
January 18, 2018 - Oncologists Dish on Top Issues for 2018
January 18, 2018 - Researchers identify new potential drug target for Huntington’s disease
January 18, 2018 - Metrohm USA welcomes employees to new headquarters in Florida
January 18, 2018 - Human waste remains main source of fecal pollution in the river Danube
January 18, 2018 - Expert discusses how to stay healthy during flu season
January 18, 2018 - New biomaterials-based system improves T-cell production
Regeneron forms consortium to accelerate largest widely-available human sequencing resource

Regeneron forms consortium to accelerate largest widely-available human sequencing resource

image_pdfDownload PDFimage_print

Regeneron Pharmaceuticals, Inc. along with new collaborators AbbVie, Alnylam Pharmaceuticals, AstraZeneca, Biogen and Pfizer Inc., today announced the formation of a major ‘pre-competitive’ consortium to fund the generation of genetic exome sequence data from the 500,000 volunteer participants who make up the UK Biobank health resource.

The newly announced collaborators will each commit $10 million to enable a dramatic acceleration of sequencing timelines, and additional companies are considering joining the consortium. Regeneron will conduct the sequencing effort. The sequencing data will be paired with detailed, de-identified medical and health records within the UK Biobank resource, including enhanced measures such as brain, heart and body imaging, to create an unparalleled resource for linking human genetic variations to human biology and disease.

It was originally planned that sequencing of all 500,000 samples in the UK Biobank would be completed by 2022, with the first 50,000 people sequenced during 2017 with funding from Regeneron and GlaxoSmithKline. Now, by engaging several leading Life Sciences companies to form this new consortium, it will be possible to complete the exome sequencing of all 500,000 participants by the end of 2019, with all data made broadly available by UK Biobank to researchers by the end of 2020.

This consortium effort thus greatly accelerates delivery to the global scientific community of the largest ‘big data’ resource linking human sequence data to other health-related information. Sequencing of UK Biobank’s samples will continue to be performed at the Regeneron Genetics Center (RGC) facility, one of the world’s largest and most sophisticated human genetics sequencing centers.

“With mounting national and global health concerns due to widespread increases in obesity-related diseases like diabetes, and age-related diseases such as dementia, together with the ongoing threats of cardiovascular disease, cancer and infectious agents, it is a great statement that so many leading Life Sciences companies are willing to put aside their individual differences and come together to bring this unprecedented, pre-competitive ‘big data’ resource to the world. We all hope and believe this will greatly accelerate our collective efforts to make a profound impact on human health,” said George D. Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron.

This effort is a tribute to the incredible vision of UK Biobank’s funders – the Wellcome Trust and the UK Medical Research Council – in creating UK Biobank, as well as to the high-throughput and automated gene sequencing capabilities built by our team at the Regeneron Genetics Center, which is enabling the scale and speed of the project.”

“UK Biobank is truly a world-class resource thanks to the multitude of volunteer participants who have enabled us to build one of the world’s largest secure databases of health, lifestyle, medical and biological data,” said Sir Rory Collins, UK Biobank Principal Investigator and British Heart Foundation Professor of Medicine & Epidemiology at Oxford University. “We welcome the collaboration and commitment of this industrial consortium, which will yield exome sequence data for all 500,000 participants over the next few years, maximizing the potential of these data for researchers. I cannot overstate the impact this information is likely to have on improving the treatment and prevention of disease.”

Consortium members will have a limited period of exclusive access to the sequencing data, before the data will be made available to other health researchers by UK Biobank. Consortium members have committed to make all significant research findings public.

We’re proud to have gathered a consortium of industry leaders who recognize the significance of early-stage, transparent research, and who want to make a difference for patients by developing this resource together with UK Biobank,”

Aris Baras, M.D., Vice President and Head of the Regeneron Genetics Center.

“We look forward to the trove of meaningful data that this effort will yield, given our shared belief in the power of genetics to deliver innovative new medicines.” Genetic evidence has revolutionized scientific discovery and drug development in recent years by providing clear links between certain genes and disease.

Currently, an estimated 90 percent of potential medicines entering clinical trials fail to demonstrate the necessary efficacy and safety, and never reach patients. Many of these failures are due to incomplete understanding of the link between the biological target of a drug and human disease. By contrast, medicines developed with human genetic evidence have had substantially higher success rates and patient care has benefited.

Many of Regeneron’s approved and investigational drugs have been informed by human genetics data. In addition, the RGC’s foundational collaboration with Geisinger Health System is gathering and sequencing genetic data from hundreds of thousands of people, and is already facilitating the return of validated health information to patients. The UK Biobank exome sequencing project builds on previously completed genotyping that was conducted on the 500,000 samples and released publicly in mid-2017.

Genotyping measures specific “letters” in DNA at select locations across the genome. Exome sequencing records every letter in the DNA of the exome, the 1-2 percent (30 to 40 million letters) of the genome that encodes all known proteins and that is believed to have the most relevance for therapeutic development and understanding of inherited disease. Sequencing of the entire genome of UK Biobank participants is also being planned, but it is anticipated that this will not be completed for several years after the completion of this exome sequencing effort.

Partner Statements: “We are excited to participate in this critically important initiative with Regeneron, the UK Biobank, and other industry partners,” said John Maraganore, Ph.D., Chief Executive Officer of Alnylam Pharmaceuticals. “In our view, modern drug discovery and development must include human genetic data, and there’s no current richer resource than that provided through this effort.

Indeed, broad and ongoing access to detailed health and full exome sequencing data for the 500,000 UK Biobank participants will greatly enhance Alnylam’s target identification and validation efforts, contributing to the sustainability of our RNAi therapeutics product engine.” “Discoveries derived from the study of the human genome have brought us advanced knowledge to treat disease,” said Michael Severino, M.D., executive vice president, research and development and chief scientific officer, AbbVie.

“AbbVie is proud to partner with this consortium to create an unparalleled resource to fuel human genetics research. Our focus on developing new, cutting-edge treatments for some of the world’s most complex medical conditions will be aided by the discoveries enabled by this collaborative effort.”

“We are proud to contribute to the advancement of genetic research by joining this important initiative, which is poised to potentially provide new insights into human health and could help guide the research efforts of Pfizer and our consortium partners as we continually work toward our shared mission of bringing new therapies to patients in need,” said Morten Sogaard, Vice President, Genome Sciences and Technologies at Pfizer.

“As pioneers in neuroscience, we are committed to developing therapies to treat debilitating CNS diseases with few treatment options,” said Michael Ehlers, M.D., Ph.D., Executive Vice President, Head of Research & Development of Biogen. “We are excited about the formation of this consortium and look forward to working with other industry partners to better understand the impact of protein coding variants on human health and disease as we advance the discovery of novel therapeutics.”

“At AstraZeneca we are discovering new medicines by analysing two million genomes, working with pioneering global partners and sequencing 500,000 samples from our own clinical trials. This exciting new partnership demonstrates our shared ambition to discover genetic drivers of disease, delivering innovative, impactful treatments to patients,” said Ruth March, Ph.D., Vice President and Head of Precision Medicine and Genomics at AstraZeneca.

UK Biobank is the most comprehensive resource of its kind in the world. Its 500,000 participants have provided information about their health, well-being and lifestyle, as well as blood and other biological samples for long-term storage and analysis. In addition, they have agreed to have their health followed through medical records for many years. Scientists from around the world are able to use anonymized data from the resource for research intended to improve the prevention and treatment of a wide range of common disorders.

UK Biobank is funded primarily by the UK Medical Research Council and the Wellcome Trust.

Tagged with:

About author

Related Articles